CoChat

Levetiracetam Mechanisms of Action: From Molecules to Systems

Open access
Contreras-García, Itzel Jatziri, Cárdenas-Rodríguez, Noemí, Romo-Mancillas, Antonio, Bandala, Cindy, Zamudio, Sergio R., Gómez-Manzo, Saúl, Hernández-Ochoa, Beatriz, Mendoza-Torreblanca, Julieta Griselda, Pichardo-Macías, Luz Adriana · 2022 · Pharmaceuticals

The DOI matches its Crossref record; 302 of the 303 references it cites were found in a registry or an index.

Abstract

Epilepsy is a chronic disease that affects millions of people worldwide. Antiepileptic drugs (AEDs) are used to control seizures. Even though parts of their mechanisms of action are known, there are still components that need to be studied. Therefore, the search for novel drugs, new molecular targets, and a better understanding of the mechanisms of action of existing drugs is still crucial. Levetiracetam (LEV) is an AED that has been shown to be effective in seizure control and is well-tolerable, with a novel mechanism of action through an interaction with the synaptic vesicle protein 2A (SV2A). Moreover, LEV has other molecular targets that involve calcium homeostasis, the GABAergic system, and AMPA receptors among others, that might be integrated into a single mechanism of action that could explain the antiepileptogenic, anti-inflammatory, neuroprotective, and antioxidant properties of LEV. This puts it as a possible multitarget drug with clinical applications other than for epilepsy. According to the above, the objective of this work was to carry out a comprehensive and integrative review of LEV in relation to its clinical uses, structural properties, therapeutical targets, and different molecular, genetic, and systemic action mechanisms in order to consider LEV as a candidate for drug repurposing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ph15040475

Cites

302 of 302 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Chemical structures of racetams and molecular modifications. (A) Molecular structures of different SV2A ligands used in the text. (B) SAR map reported by Mittrapalli, 2014. (C) Updated SAR map according to our bibliographic search.
Figure 1 Chemical structures of racetams and molecular modifications. (A) Molecular structures of different SV2A ligands used in the text. (B) SAR map reported by Mittrapalli, 2014. (C) Updated SAR map according to our bibliographic search.CC BY · PubMed Central
Figure 2 Schematic representation of the racetam binding site in SV2A found by molecular modeling. Despite having the same components, LEV binds differently than the rest of the racetams in a pocket in front of the racetam binding site that had some polar amino acids that can interact with polar groups in position 4, as in UCB-30889.
Figure 2 Schematic representation of the racetam binding site in SV2A found by molecular modeling. Despite having the same components, LEV binds differently than the rest of the racetams in a pocket in front of the racetam binding site that had some polar amino acids that can interact with polar groups in position 4, as in UCB-30889.CC BY · PubMed Central
Figure 3 SV2A function. SV2A regulates the readily releasable pool (RRP) size (1) and during priming (2) facilitates the progression to the release-competent state, both allowing normal neurotransmission. In the exocytosis (3), SV2A functions as a target for residual calcium and finally, in the endocytosis (4), regulates the vesicle content of the calcium-sensor synaptotagmin protein.
Figure 3 SV2A function. SV2A regulates the readily releasable pool (RRP) size (1) and during priming (2) facilitates the progression to the release-competent state, both allowing normal neurotransmission. In the exocytosis (3), SV2A functions as a target for residual calcium and finally, in the endocytosis (4), regulates the vesicle content of the calcium-sensor synaptotagmin protein.CC BY · PubMed Central
Figure 4 Hypothetical integrated molecular mechanisms of action of LEV. (1) LEV diffuses throughout the blood–brain barrier and neuron membrane or enters during (2) exocytosis and endocytosis processes, subsequently exerts its action by various mechanisms. (3) LEV could decrease the function of SV2A during vesicular priming and thus diminishes the readily releasable pool and therefore the release of neurotransmitters (purple terminal). Another possibility is that LEV stabilizes SV2A and improves its function during (4) exocytosis, and (5) endocytosis modulating the expression and traffic of synaptotagmin protein. (6) Moreover, it has been reported that LEV blocks the voltage-dependent calcium channels, decreasing the synaptic transmission. (7) LEV reduces potassium currents inducing a decrease in the repetitive action potential generation. With respect to calcium intracellular systems, LEV reduces the calcium transients of (8) ryanodine and (9) IP3 receptors. In the GABAergic system, LEV modulates the region-dependent (10) glutamic acid decarboxylase (GAD) and increases (11) GABA transaminase (GABA-T). In the post-synapse, LEV blocks the effect of the (12) GABAA receptor antagonists. In the glutamatergic synapse, LEV modulates (13) AMPA receptors and decreases the excitatory current. (14) Finally, LEV interacts with noradrenaline, adenosine and serotonin receptors in post-synapse involved in pain system.
Figure 4 Hypothetical integrated molecular mechanisms of action of LEV. (1) LEV diffuses throughout the blood–brain barrier and neuron membrane or enters during (2) exocytosis and endocytosis processes, subsequently exerts its action by various mechanisms. (3) LEV could decrease the function of SV2A during vesicular priming and thus diminishes the readily releasable pool and therefore the release of neurotransmitters (purple terminal). Another possibility is that LEV stabilizes SV2A and improves its function during (4) exocytosis, and (5) endocytosis modulating the expression and traffic of synaptotagmin protein. (6) Moreover, it has been reported that LEV blocks the voltage-dependent calcium channels, decreasing the synaptic transmission. (7) LEV reduces potassium currents inducing a decrease in the repetitive action potential generation. With respect to calcium intracellular systems, LEV reduces the calcium transients of (8) ryanodine and (9) IP3 receptors. In the GABAergic system, LEV modulates the region-dependent (10) glutamic acid decarboxylase (GAD) and increases (11) GABA transaminase (GABA-T). In the post-synapse, LEV blocks the effect of the (12) GABAA receptor antagonists. In the glutamatergic synapse, LEV modulates (13) AMPA receptors and decreases the excitatory current. (14) Finally, LEV interacts with noradrenaline, adenosine and serotonin receptors in post-synapse involved in pain system.CC BY · PubMed Central
Figure 5 Hypothetical acti-ictogenic and neuroprotector effect of levetiracetam (LEV). (A) The anti-ictogenic effect of LEV seems to be an integrative mechanism, that involved the interaction to this AED with different pharmacological targets, resulting in a decrease in the excitability in the epileptic circuit. Although the exact mechanism throughout LEV can decrease the excitability remain unclear, the evidence suggests that SV2A plays a critical role. In epileptic nerve terminal, the binding LEV-SV2A could result in augment or decrease in neurotransmitter release. Moreover, LEV blocks the voltage calcium and decreases the release of the neurotransmitters. (B) GABA and glutamate are the principal neurotransmitters responsible for maintaining a balance between inhibition and excitation, respectively. In epilepsy, as well as in other pathologies that cause neuronal damage, there is an imbalance between these systems, which results in increased excitability and neuronal death. LEV decreases both events, perhaps by modulating neurotransmitter release by binding to SV2A, which may result in increased neurotransmitter release, particularly GABA, or in a decreased of neurotransmitter release, particularly glutamate. Regardless, whether LEV particularly increases GABA release or decreases glutamate release, the final effect is decreased excitability, seizures, and neuronal death by restored the balance between excitatory and inhibitory systems.
Figure 5 Hypothetical acti-ictogenic and neuroprotector effect of levetiracetam (LEV). (A) The anti-ictogenic effect of LEV seems to be an integrative mechanism, that involved the interaction to this AED with different pharmacological targets, resulting in a decrease in the excitability in the epileptic circuit. Although the exact mechanism throughout LEV can decrease the excitability remain unclear, the evidence suggests that SV2A plays a critical role. In epileptic nerve terminal, the binding LEV-SV2A could result in augment or decrease in neurotransmitter release. Moreover, LEV blocks the voltage calcium and decreases the release of the neurotransmitters. (B) GABA and glutamate are the principal neurotransmitters responsible for maintaining a balance between inhibition and excitation, respectively. In epilepsy, as well as in other pathologies that cause neuronal damage, there is an imbalance between these systems, which results in increased excitability and neuronal death. LEV decreases both events, perhaps by modulating neurotransmitter release by binding to SV2A, which may result in increased neurotransmitter release, particularly GABA, or in a decreased of neurotransmitter release, particularly glutamate. Regardless, whether LEV particularly increases GABA release or decreases glutamate release, the final effect is decreased excitability, seizures, and neuronal death by restored the balance between excitatory and inhibitory systems.CC BY · PubMed Central
Figure 6 Putative antiepiletogenic levetiracetam (LEV) mechanism. (A) LEV is one of the few antiepileptic drugs (AED) able to retard or inhibit the generation of epileptic neural circuits. The mechanism through which it does is not completely elucidated, but apparently inhibiting the excessive synaptic transmission. (B) The binding LEV-SV2A improve the SV2A effects, diminishing the hyperexcitability and thus delays epileptogenesis. (C) LEV inhibit epileptic foci formation by suppressing BDNF synthesis and consequently the mossy fiber sprouting.
Figure 6 Putative antiepiletogenic levetiracetam (LEV) mechanism. (A) LEV is one of the few antiepileptic drugs (AED) able to retard or inhibit the generation of epileptic neural circuits. The mechanism through which it does is not completely elucidated, but apparently inhibiting the excessive synaptic transmission. (B) The binding LEV-SV2A improve the SV2A effects, diminishing the hyperexcitability and thus delays epileptogenesis. (C) LEV inhibit epileptic foci formation by suppressing BDNF synthesis and consequently the mossy fiber sprouting.CC BY · PubMed Central
Figure 7 Anti-inflammatory effect of LEV. Seizures induces the activation of microglia, which in turn releases proinflammatory mediators, such as TNF-α, IL-1β, IL-6, etc. These cytokines promote the brain blood– brain barrier (BBB) damage and sustained neuronal inflammation leading to seizures and neurodegeneration, which activates further inflammation, establishing a vicious circle. The anti-inflammatory mechanism of LEV may be related to the voltage-activated Ca2+ channel inhibition present in the microglia (purple cell). This results in glia non-activation and thus the attenuation of inflammation. LEV also inhibits the JAK2-STAT3 signaling pathway. LEV can act as an HDAC inhibitor promoting the transcription of antioxidant and cytoprotective genes, restoring the oxidation–reduction balance.
Figure 7 Anti-inflammatory effect of LEV. Seizures induces the activation of microglia, which in turn releases proinflammatory mediators, such as TNF-α, IL-1β, IL-6, etc. These cytokines promote the brain blood– brain barrier (BBB) damage and sustained neuronal inflammation leading to seizures and neurodegeneration, which activates further inflammation, establishing a vicious circle. The anti-inflammatory mechanism of LEV may be related to the voltage-activated Ca2+ channel inhibition present in the microglia (purple cell). This results in glia non-activation and thus the attenuation of inflammation. LEV also inhibits the JAK2-STAT3 signaling pathway. LEV can act as an HDAC inhibitor promoting the transcription of antioxidant and cytoprotective genes, restoring the oxidation–reduction balance.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Christine, A.G., and Devaskar, S.U. (2012). Chapter 61—Central Nervous System Injury and Neuroprotection. Avery’s Diseases of the Newborn (Ninth Edition), W.B. Saunders.

Cited by

See all 146

Metadata

Authors
Contreras-García, I. J., Cárdenas-Rodríguez, N., Romo-Mancillas, A., Bandala, C., Zamudio, S. R., Gómez-Manzo, S., Hernández-Ochoa, B., Mendoza-Torreblanca, J. G., & Pichardo-Macías, L. A.
Affiliations
  • Laboratorio de Fisiología, Escuela Militar de Graduados de Sanidad, Ciudad de México 11200, Mexico
  • Laboratorio de Neurociencias, Subdirección de Medicina Experimental, Instituto Nacional de Pediatría, Ciudad de México 04530, Mexico
  • Laboratorio de Diseño Asistido por Computadora y Síntesis de Fármacos, Facultad de Química, Universidad Autónoma de Querétaro, Centro Universitario, Querétaro 76010, Mexico
  • Secretaria de Salud (MX)
  • Instituto Politécnico Nacional (MX)
  • Laboratorio de Bioquímica Genética, Instituto Nacional de Pediatría, Secretaría de Salud, Ciudad de México 04530, Mexico
  • Laboratorio de Inmunoquímica, Hospital Infantil de México Federico Gómez, Secretaría de Salud, Ciudad de México 06720, Mexico
  • Departamento de Fisiología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México 07738, Mexico
Venue
Pharmaceuticals
Publisher
MDPI AG
Published
2022-04-13
Volume
15
Issue
4
Pages
475
ISSN
1424-8247 (ISSN-L)
OpenAlex
W4223993843
Cited by
131
References
303
Citations by year
2026: 28 · 2025: 45 · 2024: 37 · 2023: 21
FWCI
4.43
Type
journal article
Language
en
Open access
Locations
  • Pharmaceuticals (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
Keywords
levetiracetam, antiepileptic drugs, epilepsy, seizure control, SV2A, calcium homeostasis, GABAergic system, AMPA receptors, multi-target drugs, drug repurposing, neuroprotection, anti-inflammatory activity, antioxidant activity, molecular targets

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.